Article

Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variability

2026-08-31

Abstract excerpt

Background Fluid biomarkers enable the demonstration of the biological effects of novel therapies in Alzheimers disease (AD). However, longitudinal biomarker data are sparse and sample size calculations for fluid biomarkers are often lacking. Here, we provided longitudinal CSF and plasma AD biomarkers measured in samples collected in a placebo arm in a 1.5-year phase 2b trial, allowing us to study natural trajecto...

Identifiers and source

Literature Corpus work: f4dab1ea-2712-5a9d-a928-710e317c79f6
DOI: 10.64898/2026.08.27.26361425

Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest

Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variabilityDOI 10.64898/2026.08.27.26361425Read

Timing of changes in Alzheimer’s disease plasma biomarkers as assessed by amyloid and tau PET clocksSemantic proximity Read

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer’s disease: sequence and timingSemantic proximity Read

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s diseaseSemantic proximity Read

Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer’s DiseaseSemantic proximity Read

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read

Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinicsSemantic proximity Read

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseaseSemantic proximity Read

CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signaturesSemantic proximity Read

Plasma biomarker trajectories: Impact of AD genetic risk and clinical progressionSemantic proximity Read